A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy

Health Economics

Volumn 6, Issue 6, 1997, Pages 589-601

  Morris, Stephen ^a  

^a CITY UNIVERSITY   (United Kingdom)

Author keywords

Cholesterol modifying pharmacotherapy; Clinical trials; Coronary heart disease; Economic modelling

Indexed keywords

CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; PLACEBO;

ACCURACY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; ECONOMIC EVALUATION; HEART INFARCTION; INCIDENCE; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL MODEL; UNITED KINGDOM;

ANTICHOLESTEREMIC AGENTS; CLINICAL TRIALS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DOUBLE-BLIND METHOD; HUMANS; INCIDENCE; MALE; MASSACHUSETTS; MIDDLE AGED; MODELS, ECONOMIC; MYOCARDIAL INFARCTION; PRAVASTATIN; RANDOMIZED CONTROLLED TRIALS; RISK; SCOTLAND; SURVIVAL ANALYSIS;

EID: 0031449962     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1050(199711)6:6<589::AID-HEC286>3.0.CO;2-D     Document Type: Article

References (57)

1. Law, M. R., Wald, N. J., Wu, T., Hackshaw, A. and Bailey, A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. British Medical Journal 1994; 308: 363-366.
2. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Circulation 1994; 89: 1333-1445.
3. Tunstall-Pedoe, H., Smith, W. C. and Tavendale, R. How-often-that-high graphs of serum cholesterol: findings from the Scottish heart health and Scottish MONICA studies. Lancet 1989; i: 540-542.
4. Office of Population Censuses and Surveys (OPCS). Mortality Statistics: Cause, Series DH2 No. 19; 1992. London: HMSO, 1993.
5. O'Brien, B. Cholesterol and Coronary Heart Disease: Consensus or Controversy. London: Office of Health Economics, 1991.
6. Oster, G., Borok, G. M., Menzin, J., Heyse, J. F., Epstein, R. S., Quinn, V., Benson, V., Dudl, J. and Epstein, A. A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS). Controlled Clinical Trials 1994; 14: 255-260.
7. Rittenhouse, B. Uses of Models in Economic Evaluations of Medicines and Other Health Technologies. London: Office of Health Economics, 1996.
8. Glick, H., Kinosian, B. and Schulman, K. Decision analytic modelling: some uses in the evaluation of new pharmaceuticals. Drug Information Journal 1994; 28: 691-707.
9. Sheldon, T. Problems of using modelling in the economic evaluation of health care. Health Economics 1996; 5: 1-11.
10. Jonsson, B., Johannesson, M., Kjekshurst, J., Olsson, A. G., Pedersen, T. R. and Wedel, H. for the Scandinavian Simvastatin Survival Study Group. Cost-effectiveness of cholesterol-lowering: results from the Scandinavian Simvastatin Survival Study. European Heart Journal 1996; 17: 1001-1007.
11. Drummond, M. F., McGuire, A. and Fletcher, A. Economic Evaluation of Drug Therapy for Hypercholesterolemia in the UK. University of York CHE Discussion Paper 104, 1993.
12. Oster, G. and Epstein, A. Cost-effectiveness of antihyperlipidemic therapy in the prevention of coronary heart disease: the case of cholestyramine. Journal of the American Medical Association 1987; 258: 2381-2387.
13. Martens, L. L., Rutten, F. H., Erkelens, D. W. and Ascoop, C. A. Cost effectiveness of cholesterol-lowering therapy in The Netherlands: simvastatin versus cholestyramine. American Journal of Medicine 1989; 87 (Suppl. 4A): 54S-58S.
14. Martens, L. L., Rutten, F. H., Erkelens, D. W. and Ascoop, C. A. Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands. American Journal of Cardiology 1990; 65: 27F-32F.
15. Kristiansen, I. S., Eggen, A. E. and Thelle, D. S. Cost-effectiveness of incremental programmes for lowering cholesterol concentration: is individual intervention worthwhile? British Medical Journal 1991; 302: 1119-22.
16. Ashraf, T., Hay, J. W., Pitt, B., Wittels, E., Crouse, J., Davidson, M., Furberg, C. D. and Radican, L. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. American Journal of Cardiology 1996; 78: 409-414.
17. Assman, G. and Schulte, H. Primary prevention of coronary heart disease in the Federal Republic of Germany: a cost-effectiveness analysis. In: Lewis B. and Assman G (eds). The Social and Economic Context of Coronary Prevention. Current Medical Literature: Proc Int Taskforce Prev CHD, 1989.
18. Berwick, D. M., Cretin, S. and Keeler, T. Cholesterol, children and heart disease: an analysis of alternatives. Pediatrics 1981; 68: 721-730.
19. Blum, C. B. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. American Journal of Cardiology 1994; 73: 3D-11D.
20. Byers, T., Mullis, R., Anderson, J., Dusenbury, L., Gorsky, R., Kimber, C., Krueger, K., Kuester, S., Mokdad, A., Perry, G. and Smith, C.A. The cost and effects of a nutritional education program following work-site cholesterol screening. American Journal of Public Health 1995; 85: 650-655.
21. Field, K. Thorogood, M., Silagy, C., Normand, C., O'Neill, C. and Muir, J. Strategies for reducing coronary risk factors in primary care: which is most cost-effective? British Medical Journal 1995; 310: 1109-1112.
22. Garber, A. M. Littenberg, B., Sox, H. C., Wagner, J. L. and Gluck, M. Costs and health consequences of cholesterol screening for asymptomatic older Americans. Archives of Internal Medicine 1991; 151: 1089-1095.
23. Gardner, S. F., Schneider, E. F., Granberry, M. C. and Carter, I. R. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy 1996; 16: 419-423.
24. Goldman, L., Weinstein, M. C., Goldman, P. and Williams, L. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. Journal of the American Medical Association 1991; 265: 1145-1151.
25. Haasis, R., Berger, J., Andersson, F., Kartman, B. and Juan, J. A pharmacoeconomic evaluation of fluvastatin and lovastatin in primary hypercholesterolemia. British Journal of Medical Economics 1996; 10: 145-157.
26. Hall, J. P. Heller, R. F., Dobson, A. J., Lloyd, D. M., Sanson-Fisher, R. W. and Leeder, S. R. A cost-effectiveness analysis of alternative strategies for the prevention of heart disease. Medical Journal of Australia 1988; 148: 273-277.
27. Hamilton, V. H., Racicot, F. E., Zowall, H., Coupal, L. and Grover, S. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Journal of the American Medical Association 1995; 273: 1032-1038.
28. Hay, J., Wittels, E. and Gotto, A. An economic evaluation of Lovastatin for cholesterol lowering and coronary artery disease reduction. American Journal of Cardiology 1991; 67: 789-796.
29. Heudebert, G. R., Van Ruiswyk, J., Hiatt, J. and Schectman, G. Combination therapy for hypercholesterolemia: the trade-off between cost and simplicity. Archives of Internal Medicine 1993; 153: 1828-1837.
30. Himmelstein, D. U. and Woolhandler, S. Free care, cholestyramine and health policy. New England Journal of Medicine 1984; 311: 1511-1514.
31. Hjalte, K., Lindgren, B., Persson, U. and Olsson, A. G. Lipid-lowering therapy: cost estimates in Sweden. In: Lewis B. and Assman G (eds). The Social and Economic Context of Coronary Prevention. Current Medical Literature: Proc Int Taskforce Prev CHD, 1989.
32. Hjalte, K., Lindgren, B. and Persson, U. Cost-effectiveness of simvastatin versus cholestyramine: results for Sweden. PharmacoEconomics 1992; 1: 213-216.
33. Johannesson, M., Borgquist, L., Jonsson, B. and Lindholm, L. H. The cost-effectiveness of lipid lowering in Swedish primary health care. Journal of Internal Medicine 1996; 240: 23-29.
34. Kinlay, S., O'Connell, D., Evans, D. and Halliday, J. The cost-effectiveness of different blood-cholesterol-lowering strategies in the prevention of coronary heart disease. Australian Journal of Public Health 1994; 18: 105-110.
35. Kinosian, B. and Eisenberg, J. Cutting into cholesterol: cost-effective alternatives for treating hypercholesterolemia. Journal of the American Medical Association 1988; 259: 2249-2254.
36. Lim, M. C. and Foo, W. M. Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidemia. Annals of Academic Medicine 1992; 21: 34-37.
37. Lovastatin Pravastatin Group and Farbstein, S. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. American Journal of Cardiology 1993; 71: 810-815.
38. Martens, L. and Guibert, R. Cost-effectiveness of lipid-modifying therapy in Canada: comparison of HMG-CoA rductase inhibitors in the primary prevention of coronary heart disease. Clinical Therapeutics 1994; 16: 1052-1062.
39. Pharoah, P. D. and Hollingworth, W. Cost-effectiveness of lowering cholesterol with statins in patients with and without pre-existing coronary heart disease. British Medical Journal 1996; 312: 1443-1448.
40. Reckless, J. Cost-effectiveness of clinical care for hyperlipidemia. In: Lewis B. and Assman G (eds). The Social and Economic Context of Coronary Prevention. Current Medical Literature: Proc Int Taskforce Prev CHD, 1989.
41. Reckless, J. Cost-effectiveness of hypolipidaemic drugs. Postgraduate Medical Journal 1993; 69 (Suppl. 1): S30-S33.
42. Schrott, H. G., Stein, E. A., Dujovne, C. A., Davidson, M. H., Goris, G. B., Oliphant, T. H., Phillips, J. C. and Shawaryn, G. G. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. American Journal of Cardiology 1995; 75: 34-39.
43. Schulman, K. A., Kinosian, B., Jacobson, T. A., Glick, H., William, M. K., Koffer, H. and Eisenberg, J. M. Reducing high blood cholesterol level with drugs: cost-effectiveness of pharmacologic management. Journal of the American Medical Association 1990; 264: 3025-3033.
44. Standing Medical Advisory Committee. Blood Cholesterol Testing: the Cost-Effectiveness of Opportunistic Cholesterol Testing. Report by the Standing Medical Advisory Committee to the Secretary of State for Health, May 1990.
45. Tomson, Y., Johannesson, M. and Aberg, H. The costs and effects of two different lipid intervention programmes in primary health care. Journal of Internal Medicine 1995; 237: 13-17.
46. Weinstein, M. and Stason, W. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annual Review of Public Health 1985; 6: 41-63.
47. Abbott, R. D. and McGee, D. Section 37: the probability of developing certain cardiovascular diseases in eight years at specified values of some characteristics. In: Kannell, W. B., Woolf, P. A. and Garrison, R. J. (eds). The Framingham Study: an Epidemiological Investigation of Cardiovascular Disease. US Department of Health, Education and Welfare Publication NIH 87-2703. Bethseda, MD: Public Health Services, 1987.
48. Anderson, D. M., Wilson, P. W., Odell, P. M. and Kannell, W. B. An updated coronary risk profile: a statement for health professionals. Circulation 1991; 83; 356-362.
49. Keys, A., Aravanis, C., Blackburn, H., Van Buchem, F. S., Buzina, R. and Djordjevic, B. S. Probability of middle-aged men developing coronary heart disease in five years. Circulation 1972; 45: 815-828.
50. Schulte, H. and Assman, G. CHD risk equations obtained from the Framingham Heart Study applied to PROCAM study. Cardiovascular Risk Factors 1991; 1: 126-133.
51. Manninen, V., Flo, M. O. and Frick, M. H. Lipid alterations and the decline in the incidence of coronary heart disease in the Helsinki Heart Study. Journal of the American Medical Association 1988; 260: 641-651.
52. West of Scotland Coronary Prevention Study Group. A coronary primary prevention study of Scottish men aged 45-65 years trial design. Journal of Clinical Epidemiology 1992; 45: 849-860.
53. West of Scotland Coronary Prevention Study Group. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. American Journal of Cardiology 1995; 76: 485-491.
54. Shepherd, J. Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., MacFarlane, P. W., McKillop, J. H. and Packard, C. J. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New England Journal of Medicine 1995; 333: 1301-1307.
55. Hartunian, N. S., Smart, C. N. and Thompson, M. S. The Incidence and Economic Costs of Major Health Impairments. Massachusetts: Lexington Books, 1981.
56. MIMS. Monthly Index of Medical Specialties. London: Medical Publications, 1996.
57. Piercy, J. and Philips, Z. Costing of Cardiology Services, Report Z9930. York: York Health Economics Consortium, 1995.